NPPA revises ceiling prices of 33 scheduled drugs

Notified ceiling prices of 33 scheduled formulations of Schedule-I under Drugs (Prices Control) Amendment Order, 2017 are cetirizine capsule, phenytoin capsule, phenytoin
er capsule, cefixime capsule, zidovudine capsule, procarbazine tablet, betamethasone gel, omeprazole tablet, 
phenytoin oral liquid, povidone iodine solution, omeprazole powder for injection, gentamicin injection, rifampicin oral liquid, streptomycin powder for injection, clotrimazole pessary, zidovudine + lamivudine + nevirapine tablet, permethrin lotion, omeprazole capsule, bisacodyl suppository, methylergometrine tablet, phenytoin capsule, tetanus toxoid injection, methylprednisolone injection, paracetamol injection
dexamethasone injection and albendazole oral liquid. 

The concerned manufacturers of these formulations shall furnish quarterly return to the NPPA, in respect of production/import and sale of product in Form-III of Schedule-II of the DPCO, 2013 through IPDMS. Manufacturers in case intending to discontinue above said formulations, shall furnish information to the NPPA, in respect of discontinuation of the production and/or import of above said formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of discontinuation.

In case the retail price of any of the formulations is not complied with, as per instant price notification and notes specified, then the concerned manufacturer/marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955.

Consequent to the issue of retail price of the formulations as specified in this notification, the price order(s) if any, issued for concerned manufacturer/marketeer prior to said date of notification, stand(s) superseded.

Nppa revises ceiling prices, scheduled drugs